ORIGINAL RESEARCH
Efficacy of commercial bacteriophage products against ESKAPE pathogens
Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia
Correspondence should be addressed: Nikita S. Kuptsov
Malaya Pirogovskaya, 1a, Moscow, 119435; moc.liamg@snvostpuk
Funding: all study expenses were covered by the funds allocated for the State Assignment on the Development of a personalized approach to the therapy of infections using virulent bacteriophages (Code: Bacteriophage).
Acknowledgements: the authors thank the Center for Precision Genome Editing and Genetic Technologies for Biomedicine, the Federal Research and Clinical Center of Physical-Chemical Medicine of the Federal Medical Biological Agency for their help with bacterial gene sequencing and for subsequent multilocus sequencing typing.
Author contribution: Kuptsov NS — study plan; data acquisition and analysis; manuscript preparation; Kornienko MA — study plan; data analysis; manuscript preparation; Gorodnichev RB, Parfenova TV — data acquisition and analysis; Danilov DI, Malakhova MV — data acquisition; Makarenko GI — sample collection; Shitikov EA — data analysis; manuscript preparation; Ilina EN — manuscript preparation.